Imaging Progression despite Clinical Remission in Early Rheumatoid Arthritis Patients after Etanercept Interruption
2009
The aim of this preliminary study is to evaluate clinical and imaging response in twenty patients with early Rheumatoid Arthritits (eRA) treated with Etanercept (Etn) + Methotrexate (Mtx) and to investigate whether clinical and MRI remission may be maintained after biological therapy interruption. Assessment included: radiography, Visser score and anti-CCP antibodies at baseline; disease activity score in 44 joints (DAS44), rheumatoid factor (RF), Magnetic Resonance Imaging (MRI) of hands and wrists at baseline (T0), 12 (T1), and 24 months (T2). MRI was scored for synovitis, bone oedema and erosions (OMERACT study); patients who reached clinical and imaging remission at T1 were considered eligible for interrupting Etn. At T1 8/20 (40%) patients showed a total remission [DAS44 from 5 (T0) to 1.4 (T1); p<0.02], whereas the other 12/20 (60%) showed an improvement, without complete remission [DAS44 from 4.8 (T0) to 2.8 (T1); p<0.05]. Etn was therefore interrupted in the first group of patients (group A), wher...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
12
Citations
NaN
KQI